Human leukocyte antigens-DRB103 is associated with systemic lupus erythematosus and anti-SSB production in South Tunisia

Systemic lupus erythematosus (SLE) is an autoimmune disease with various presentations. This variation is due to the interaction of hormonal, environmental, and genetic factors. Associations between human leukocyte antigens and SLE have long been recognized in different ethnic populations and have b...

Full description

Saved in:
Bibliographic Details
Published in:International journal of health sciences Vol. 12; no. 1; pp. 21 - 27
Main Authors: Hachicha, Hend, Kammoun, Arwa, Mahfoudh, Nadia, Marzouk, Sameh, Feki, Sawsan, Fakhfakh, Raouia, Fourati, Hajer, Haddouk, Samy, Frikha, Faten, Gaddour, Lilia, Hakim, Feiza, Bahloul, Zouheir, Makni, Hafedh, Masmoudi, Hatem
Format: Journal Article
Language:English
Published: Saudi Arabia Qassim Uninversity 01-01-2018
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic lupus erythematosus (SLE) is an autoimmune disease with various presentations. This variation is due to the interaction of hormonal, environmental, and genetic factors. Associations between human leukocyte antigens and SLE have long been recognized in different ethnic populations and have been suggested to represent the most important association. The objectives of this paper were to determine susceptibility and protection human leukocyte antigens (HLA) Class II markers for SLE and to highlight, for the first time, associations between HLA alleles and clinical and serological features in South Tunisia. We conducted a case-control study on 75 SLE patients and 123 healthy controls. The HLA Class II DRB1/DQB1 of all patients and controls was genotyped using polymerase chain reaction-sequence specific primer technique. Statistical analysis was performed using SPSS software. HLA-DRB1*03 was the principal Class II allele associated with the genetic susceptibility to SLE (pc = 0.02; OR = 2.57; CI = [1.39-4.75]; this allele was also associated with anti-SSB production ( = 0.016; OR = 4.00; CI = [1.24-12.96]). HLA-DRB1*01 was significantly more expressed in SLE patients with neurologic disorders ( = 0.013; OR = 20.25; CI = [1.87-219.21]). No allele was found to be protective against SLE in our study group. Our results show that in South Tunisia SLE is associated with HLA-DRB1*03 and that some clinical features of SLE may be influenced by specific DRB1 and DQB1 alleles.
ISSN:1658-3639